Estrella Immunopharma Inc (ESLA) Stock Analysis
Verdict: AVOID
Early Phase I CAR-T trial progress is overshadowed by severe cash burn, negative net equity (-$10.37M), and active Nasdaq delisting warnings.
Investment score: 26/100
Analysis as of
Is Estrella Immunopharma Inc stock worth reviewing? The TradeMates thesis
The TradeMates model assigns an AVOID recommendation to Estrella Immunopharma Inc due to severe balance sheet deficits, immediate dilution risk, and Nasdaq compliance deficiencies, which outweigh early Phase I clinical trial developments.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
Estrella Immunopharma Inc opportunities and risks
What speaks for ESLA
- Phase I STARLIGHT-1 trial of EB103 demonstrated 100% complete response (CR) rate across evaluable patients in second cohort
What speaks against ESLA
- Severe liquidity shortfall and ongoing equity dilution risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ESLA | n/a | 0.0x | n/a | 0.0% | 0.0% | -21.9% |
| HOWL | n/a | 2.3x | n/a | 86.4% | -164.8% | -63.3% |
| IBIO | n/a | 461.6x | 0.3x | 100.0% | -33044.0% | -51.6% |
| BMEA | n/a | 0.0x | n/a | 0.0% | 0.0% | -108.5% |
| ANVS | n/a | 0.0x | n/a | 0.0% | 0.0% | -101.6% |
| TVGN | n/a | 0.0x | n/a | 0.0% | 0.0% | -42.8% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -63.3% |
Frequently asked questions about Estrella Immunopharma Inc (ESLA)
Is ESLA stock a good investment?
The TradeMates model rates Estrella Immunopharma Inc as AVOID with an investment score of 26/100. The TradeMates model assigns an AVOID recommendation to Estrella Immunopharma Inc due to severe balance sheet deficits, immediate dilution risk, and Nasdaq compliance deficiencies, which outweigh early Phase I clinical trial developments. This is algorithmic model output, not personal investment advice.
Is ESLA stock a buy?
The TradeMates model verdict for ESLA is AVOID with an investment score of 26/100. Treat this as a model signal to review, not a personal buy recommendation.